Metabolic events during ischaemia are probably important in determining post-ischaemic myocardial recovery. The aim of this study was to assess the effects of the ␤-blocker atenolol and the high energy demand in an ischaemia-reperfusion model free of neurohormonal and vascular factors. We exposed Langendorff-perfused isolated rat hearts to Ž . Ž . low-flow ischaemia 30 min and reflow 20 min . Three groups of hearts were used: control Ž .
Metabolic events during ischaemia are probably important in determining post-ischaemic myocardial recovery. The aim of this study was to assess the effects of the ␤-blocker atenolol and the high energy demand in an ischaemia-reperfusion model free of neurohormonal and vascular factors. We exposed Langendorff-perfused isolated rat hearts to Ž . Ž . low-flow ischaemia 30 min and reflow 20 min . Three groups of hearts were used: control Ž .
y 1 Ž . hearts n s 11 , hearts that were perfused with 2.5 g l atenolol n s 9 , and hearts electrically paced during ischaemia to distinguish the effect of heart rate from that of the Ž . drug n s 9 . The hearts were freeze-clamped at the end of reflow to determine high-energy phosphates and their metabolites. During ischaemia, the pressure-rate product was 2.3" 0.2, 5.2" 1.1, and 3.3" 0.3 mmHg 10 3 min in the control, atenolol and paced hearts, respec-Ž . tively. In addition, the ATP turnover rate, calculated from venous lactate , oxygen uptake Ž y1 . Ž y 1 . and flow, was higher in atenolol 11.2" 1.7 mol min and paced 8.1" 0.8 mol min Ž y1 . hearts than in control 6.2" 0.8 mol min . At the end of reflow, the pressure = rate product recovered 75.1" 6.4% of baseline in control¨s 54.1" 9.1 and 48.8" 4.4% in Ž . atenolol and paced hearts P-0.05 . In addition, the tissue content of ATP was higher in Ž y1 . Ž y 1 . the control hearts 15.8" 1.0 mol g than in atenolol 10.5" 2.6 mol g and paced dw dw Ž y1 . 10.9" 1.3 mol g hearts. Thus, by suppressing the protective effects of down-regudw lation, both atenolol and pacing apparently depress myocardial recovery in this model.
INTRODUCTION

Post-ischaemic myocardial recovery depends on sev-
eral not yet clarified factors, but metabolic events w x during ischaemia are probably important 1 . Ischaemic down-regulation of contractility plays a key role in linking metabolism during ischaemia to mechanical recovery during reflow. The total tissue Ž . contents of adenine nucleotides and purines TANP are maintained in isolated rat hearts during 90% flow reduction if myocardial activity is down-reguw x lated 2 . This feature, that improves post-ischaemic w x recovery regardless of free radicals scavenging 3 , is attributed to energy demand-to-supply matching. Coronary flow disturbs down-regulation: when nor-U Corresponding author. mal-flow hypoxemia replaces low-flow ischaemia, the beneficial effects of down-regulation are suppressed w x 4 . However, the role of energy demand during ischaemia is still unclear despite its relevance in pharmacological treatments that involve modulation of myocardial contractility.
␤-blockers are commonly used for the treatment w x of ischaemic heart disease 5 . Besides their neuw x w x rohormonal 6, 7 and platelet-inhibiting effects 8 , w x they decrease myocardial O consumption 9 and 2 enhance carbohydrate metabolism and energy prow x duction 10, 11 . Atenolol, a selective ␤-1 adrenergic w x 2q antagonist 12 with specific effect on Ca currents w x w x 13 and intracellular acidosis 14 , enhances mitow x chondrial ATPase activity 15 . Although ␤-blockers, propranolol and metoprolol, reduce episodes of w x transient myocardial ischaemia 16 , atenolol apparently does not protect against ischaemia-reperfusion in a model of isolated perfused heart exposed to w x global no-flow ischaemia 17 .
Ž . The aims of this study are: 1 to assess the metabolic effects of atenolol in an ischaemia-reperfusion model free of neurohormonal and vascular Ž . factors; and 2 to use atenolol as a probe to examine the effect of energy demand on post-ischaemic recovery in the same way as hypoxemia helps to understand the effect of coronary flow. Thus, besides its pharmacological value, this study may help to assess whether drug-induced changes in energy demand during ischaemia altered energy demandto-supply matching and recovery. As the heart rate was a disturbing variable between control and atenolol-perfused hearts, we also studied the effects of this variable in the absence of the drug. We show that, by increasing energy demand during ischaemia, neither atenolol nor electrical pacing are beneficial during reflow, as reflected by a depressed performance and tissue level of high-energy phosphates. This confirms that down-regulation of energy demand during ischaemia is an effective way to protect the myocardium.
MATERIALS AND METHODS
Heart perfusion
Apparatus and procedures are described elsew x Ž where 4 . Briefly, CD outbred rats Charles River, . Calco, Italy, weight 250᎐270 g were anaesthetised, hearts were excised and immediately perfused. 
Experimental design
The hearts were equilibrated for 20 min at a perfusion pressure of 100 mmHg and the volume of the intraventricular balloon was fixed to yield an EDP s 8᎐9 mmHg. After baseline measurements, hearts were exposed to ischaemia for 30 min by decreasing the pump speed to yield a perfusion pressure of 10 mmHg. Measurements were taken at the end of ischaemia with stable myocardial performance. Hearts were then reperfused for 20 min under the same conditions of baseline, measurements were taken again, and hearts were freezeclamped for metabolic assays. Hearts were divided Ž . Ž into three groups: control n s 11 , atenolol n s 9, y1 . 2.5 g l atenolol in the medium , and paced Ž n s 9, electrically paced during ischaemia at 160 " 6 y1 . Ž min . An additional group atenolol and paced, . n s 9 was designed to monitor the simultaneous effects of atenolol and pacing.
Metabolic measurements
Freeze-clamped tissue was assayed for ATP, ADP, AMP, adenosine, inosine-5Ј-monophosphate, inosine, hypoxanthine, xanthine, urate, phosphocreatine and creatine by high-pressure liquid chromatography w x Ž 18 . Calculations include: TANP sum of these sub-. stances except phosphocreatine and creatine , O 2 Ž . uptake VO , from flow, arterial and venous PO , 
Statistics
Data are expressed as mean " SE. One-way ANOVA followed by the Fisher's multiple compar-Ž ison test was performed StatView 4 software, Aba-. cus Concepts, Inc, Berkeley, CA , with the signifi-Ž . cance level set at Ps 0.05 two-tailed .
RESULTS
All hearts of the three main groups kept contracting throughout the protocol and are suitable for statistical analysis. In contrast, atenolol and paced hearts generally stopped contracting during ischaemia and could not be considered any further. Table I shows that 2.5 g l y1 atenolol did not affect performance during baseline perfusion in this model.
When perfusion pressure was reduced to 10 mmHg, coronary flow was 0.8᎐0.9 ml min y1 in the control and paced groups,¨s 1.2 ml min y1 in the To distinguish the effects of HR from those of the drug, paced hearts were stimulated at the same HR Fig. 1 . Heart rate, developed pressure, maximal rates of contraction and relaxation in control, atenolol-perfused and paced hearts. Vertical bars represent SE.
U P -0.05¨s A T P is calculated as described, it was similar in paced and control hearts, but higher in atenolol hearts. During reflow, the recovery of mechanical perfor-Ž . Fig. 2 . Venous lactate , lactate efflux, oxygen uptake and ATP production rate measured at the end of the ischaemia period in control, atenolol-perfused and paced hearts. Vertical bars represent SE.
U P-0.05¨s control Ž . ANOVA and Fisher's post-tests . mance was impaired in both atenolol and paced hearts. The tissue contents of ATP and TANP reflected mechanical recovery, but the content of phosphocreatine and phosphocreatine q creatine was the same in the three groups. The level of inosine-5Ј-monophosphate was 0.35" 0.14, 1.07" 0.49, and 0.25" 0.14 mol g y1 in control, atenolol dw Ž . and paced hearts Fig. 3 .
Due to its relatively low dose 2.5 g l , or f10 . M , atenolol did not cause any measurable effect Ž . during baseline perfusion Table I . Therefore, all the features observed in this study are directly related to the effects caused by atenolol on heart metabolism throughout ischaemia-reperfusion, thereby ruling out the well known effects related to ␤-blockade. Indeed, despite low dose, after reperfusion atenolol hearts display increased HR, flow, J , 
Model
The employed atenolol concentration allowed us to compare our results to those of previous studies w x 8, 11, 16, 19, 20 . The selected ischaemia condition induces reproducible myocardial dysfunction in control hearts without leading to arrest. This is essential to seek correlations between ischaemic down-regulation and recovery. Lack of blood in the perfusion medium excluded possible effects of atenolol on neutrophil accumulation and thrombin-induced platelet aggregation, thereby stressing its effects on cardiac metabolism. Strict temperature control Ž . " 0.5ЊC , same volume of the intraventricular balloon, and same perfusion pressure in the various groups ruled out differences in loading conditions. As animals were not pretreated, these observations relate to acute metabolic effects of atenolol on cardiac muscle.
Ischaemic down-regulation and reco¨ery
In untreated hearts during low-flow ischaemia, flow was 7᎐11% of baseline in all groups. This condition is known to induce myocardial down-reguw x lation 4 , probably due to intracellular lactate accumulation, which depresses metabolism and perforw x mance independently of pH 21 . By decreasing energy demand with respect to supply, ischaemic down-regulation would favour energy supply-to-demand matching and improve ATPrADP coupling. This would maintain the ATP pool during ischaemia w x and improve recovery during reflow 2, 22 .
Ischaemic down-regulation is apparently suppressed in atenolol hearts. In these hearts, the rates Ž . Ž . of both aerobic VO and anaerobic J paths 2 L a c during ischaemia are increased, thereby increasing w x J , in agreement with previous observations 9᎐11 . ATP 
Ž
. Moreover, the pressure = rate product reflects more than double the energy demand. This increase can not be accounted for by the 40᎐50% higher flow and supply of O . 2 Suppression of down-regulation in atenolol hearts accounts, at least in part, for impaired recovery. The lower contractility is accompanied by depressed ATP and TANP contents. High inosine-5Ј-monophosphate levels in atenolol hearts also indicate severe w x metabolic dysfunction 23 . Phosphocreatine and w x creatine do not leak across intact membrane 24 , thus the preservation of these compounds throughout ischaemia-reflow indicates that the fall observed for ATP and TANP is not due to physical membrane damage, but rather to the membrane-diffusibility of w x these compounds 2 .
The pattern observed in paced hearts reproduces Ž that observed in atenolol hearts: high pressure = . rate during ischaemia indicates suppression of down-regulation. This worsens the energy supplyto-demand imbalance, thereby impairing recovery during reflow. This chain of events closely resembles the one observed in hypoxemic hearts in previous w x studies 2 . Thus, myocardial ischaemic down-regulation may be disturbed by several events, including atenolol, electrical pacing and hypoxemia, all of which have the common feature to increase energy demand during the ischaemic stress.
Conclusion
Atenolol depresses post-ischaemic recovery in isolated perfused hearts independently of neurohormonal and blood-related effects. This effect is apparently due to the suppression of ischaemic down-regulation, which was shown to improve myocardial tolerance to ischaemia through better w x preservation of the high-energy phosphate pools 22 . Down-regulation during ischaemia may therefore play a central role in the ischaemia-reperfusion syndrome. This further stresses the importance of myocardial metabolism in determining mechanical recovery during reflow.
